Next week? A cannabis week
14. 6. 2019
New member of FNUSA-ICRC team, MVDr. Ing. Václav Trojan, Ph.D., is the Head of the Clinical-Pharmacological Unit (CPU), a certified facility that is authorized to conduct clinical trials of drugs. Under his leadership, the CPU will focus on research into cannabis, which is currently a hot topic not only among the medical community, but also among political representatives.
Next week, Dr. Trojan will participate in the Therapeutic Cannabis Symposium - Good Practice from abroad, which is held under the auspices of Prime Minister Andrej Babiš. It will be an international meeting to share the experience of experts and doctors from Israel in the field of prescribing cannabis. MUDr. Radovan Hřib, Head of the Center for Pain Management Anesthesiology and Resuscitation Clinic of FNUSA will also present his experience with this issue.
In addition to the professional symposium, our experts are also waiting for a visit to the Chamber of Deputies of the Parliament of the Czech Republic, where they will be on the agenda of negotiations on legislation on the use of medicinal cannabis and also negotiations with specific companies in the area of cooperation and technology transfer.
Annual Report in NPU II approved
13. 6. 2019
In June 2019, the 2018 report was approved in LQ1605 Translational Medicine (NPU II). We have met all the goals we have set and made considerable progress in our activities. Last year, we reported, among other things, one patent in cooperation with the MAYO Clinic, one utility model, more than 200 publications or seventeen collaborative projects with the application sphere. Foreign experts spent a total of thirty-five man-months on long-term stays here.
Also on the basis of these figures, the Ministry of Education, Youth and Sports stated that the International Clinical Research Center of St. Anne's University Hospital in Brno (FNUSA-ICRC) achieves excellent results of international importance.
The next report will be submitted in January 2020.
Faecal microbioma therapy was discussed at the partner forum
24. 5. 2019
FNUSA-ICRC held its 9th FNUSA-ICRC Partner Forum on May 20, focusing on faecal microbiom therapy and its perspectives. The meeting was attended by over 30 participants from healthcare facilities, research centers and companies specializing in the production, development and research of probiotics and prebiotics or microbiome analysis.
Faecal microbioma therapy represents the therapeutic transfer of faeces in native or processed form from donor to recipient. It is done for the treatment of the recipient, high efficacy is especially proven in the problems caused by Clostridium difficilee. However, according to recent studies, this method is also effective in addressing other diseases, such as nonspecific intestinal inflammation, as participants in the forum have shown.
MUDr. Lenka Vojtilová, Ph.D. From the Clinic of Infectious Diseases of the Faculty Hospital Brno introduces the participants with experience with faecal microbiomic therapy in the treatment of clostridial colitis and new promising indications. A comprehensive view of the microbial settlement of the human body and its relation to human health was introduced by Lenka Micenková Ph.D. from Masaryk University in Brno in a lecture entitled "Dynamics of human microbiome in health and illness".
A practical view of this issue, namely experience with the use of faecal filtrates in the treatment of idiopathic intestinal inflammation and pseudomembranous colitis, was presented by Janette Čemická from the Institute of Predictive and Personalized Medicine in Bratislava. In the end, PharmDr. Aleš Franc Ph.D. told participants about methods of enteric and colonial administration of drugs and biological material.
The Partner Forum also included an introduction to the FNUSA-ICRC activities and the presentation of the Clinical Studies Department.
MU Rector's Award was awarded to doc. Paruch
17. 5. 2019
Doc. Mgr. Kamil Paruch, Ph.D., who has been leading the FNUSA-ICRC Medicinal Chemistry research team since 2011, has been awarded the MU Rector's Award for significant creative achievement. Masaryk University is his alma mater, graduated from the Faculty of Science at MU. He then spent 13 years in the United States where he earned a doctorate in organic chemistry at Columbia University. He has also worked on research and development of new drugs in the pharmaceutical company Schering-Plow (Merck since 2009). He returned to Brno in 2009 and since then he has continued to research new organic compounds with targeted biological activity, especially in oncology. This research within FNUSA-ICRC and MU has already brought publications and patents for new drug substances with potential use as drugs for serious diseases. For example, he co-authored the first patent granted to FNUSA-ICRC in 2015: Substituted furo [3,2-b] pyridines for use as a medicament.
The prize was awarded for the development of biologically active compounds with high potential for use in practice.
FNUSA-ICRC visited by delegation from Taiwan
15. 5. 2019
The 6th Czech-Taiwan Technology Days took place in Prague on 7 May, this time focusing on smart solutions in industry, autonomous transport and medical technology. A delegation from the HSC (Healthcare Systems Consortium) in Taiwan has shown interest in visiting St. Anne's University Hospital and our center two days later.
During the visit, the FNUSA-ICRC activities were presented to them. There was also a presentation of the Taiwanese party to the FNUSA Department of Clinical Studies and IT department on new possibilities in the field of digitalisation (SelfieSign).
The visit of the American Chamber of Commerce
3. 5. 2019
At the end of April, a visit of the American Chamber of Commerce in the Czech Republic (AmCham) was organized. Its representative Katarína Bendíková and also Sales Manager of 3M Czech Republic, MSc. Mariana Ludányiová visited us.
We prepared a lab tour and showed the work of our research teams. They were most impressed by the laboratories of the Center for Translational Medicine, Department of Clinical Studies and Kardiovize 2030. The aim was to present our activities to potential business partners, which is confirmed by Mrs. Ludányiová: “Thanks to the visit, I could get acquainted with a part of the ICRC team who, with their professionalism and enthusiasm literally breathed. I would be very happy if we managed to set up a 3M R&D team with such a high-quality research center."
This meeting will be followed by another similar workshop in June, again organized by AmCham. It is a logical step - “More and more of our member companies have been recognizing the value of this research hub in the heart of Central Europe. FNUSA-ICRC is a player to be considered in R&D strategies,” adds Katarína Bendíková.